Natixis’s Theravance Biopharma TBPH Stock Holding History

Natixis’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,000	Closed	-$22.5K	–	1224
2023 Q4	$22.5K	Hold	2,000	–	–	﹤0.01%	873
2023 Q3	$17.3K	Buy	+2,000	New	+$19.3K	﹤0.01%	875

Other funds holding TBPH

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Natixis's TBPH Position: Q1 2024 in Review

Natixis sold out of Theravance Biopharma (TBPH) in Q1 2024, closing a stake of 2,000 shares — an estimated $22.5K sold.

Natixis first reported a position in TBPH in Q3 2023 and held it in 2 quarters. The position peaked at $22.5K in Q4 2023. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2024.

Natixis reported no remaining Theravance Biopharma position as of Q1 2024 after selling out during the quarter.
Natixis sold 2,000 Theravance Biopharma shares in Q1 2024, an estimated $22.5K.
Natixis first reported a position in Theravance Biopharma in Q3 2023 and held it in 2 quarters.
Natixis's Theravance Biopharma position peaked at $22.5K in Q4 2023.
121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.